OnCo
technologiesTechnologyEstablished

Proteomics instruments and affinity platforms

Machines that measure thousands of proteins at once from tissue or blood, used to find drug targets and early-detection markers.

Mass spectrometry (Thermo Fisher Orbitrap Astral, Bruker timsTOF, SCIEX ZenoTOF) and affinity-based platforms (Olink/Thermo Fisher Explore, SomaLogic/Standard BioTools SomaScan, Alamar NULISA, Nautilus and Quantum-Si single-molecule approaches) deliver deep proteomes; UK Biobank's 50,000-participant Olink dataset and CPTAC's tumour proteogenomics illustrate the discovery value. Clinical proteomic tests remain few.

Generic schematic · not to scale · placeholder for the drug discovery front
Guide RNA library · Knockout → dependency

How it works

Peptide fragmentation and mass measurement (bottom-up MS) or barcoded antibody/aptamer pairs read by sequencing or PCR quantify proteins across large dynamic ranges.

Strengths
  • Direct measurement of drug targets and post-translational state
  • Plasma proteomics at biobank scale
Limitations
  • Cost per sample
  • Dynamic range and low-abundance proteins
  • Standardisation across platforms

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Proteomics instruments and affinity platforms" OR ABSTRACT:"Proteomics instruments and affinity platforms") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Proteomics instruments and affinity platforms, not a curated reading list.

Connected

7top